A DNA vaccine for West Nile virus (WNV) was evaluated to determine whether its use could protect fish crows (Corvus ossifragus) from fatal WNV infection. Captured adult crows were given 0.5 mg of the DNA vaccine either orally or by intramuscular (IM) inoculation; control crows were inoculated or orally exposed to a placebo. After 6 weeks, crows were challenged subcutaneously with 10^5 plaque-forming units of WNV (New York 1999 strain). None of the placebo inoculated–placebo challenged birds died. While none of the 9 IM vaccine–inoculated birds died, 5 of 10 placebo-inoculated and 4 of 8 orally vaccinated birds died within 15 days after challenge. Peak viremia titers in birds with fatal WNV infection were substantially higher than those in birds that survived infection. Although oral administration of a single DNA vaccine dose failed to elicit an immune response or protect crows from WNV infection, IM administration of a single dose prevented death and was associated with reduced viremia.

West Nile virus (WNV), a mosquito-borne flavivirus, was recognized for the first time in the Western Hemisphere during summer 1999 in New York City and was associated with human, equine, and avian deaths (1–4). This virus is transmitted by a variety of mosquito species, mostly in the genus Culex (5–7). The New York 1999 strain of WNV differed genetically from other known strains of WNV except for an Israeli strain isolated from a dead goose in Israel in 1998 (1). With the exception of a laboratory study in Egypt involving hooded crows (Corvus corone) and house sparrows (Passer domesticus) (8), only these two nearly identical strains are known to kill birds (9,10). In 2000, WNV was detected in >4,000 bird carcasses in the United States (11), and the overall mortality rate was considered much greater. Several deaths attributed to WNV in the United States have occurred in valuable captive birds in zoologic collections (12). Currently, no treatment or vaccine is available for susceptible birds.

Vaccination may protect birds from lethal WNV infections. Accordingly, we examined a DNA vaccine developed for use in horses (13) for its ability to protect crows, a species known to be highly susceptible to lethal infection with this virus (8,10).

Materials and Methods

Vaccine

The plasmid DNA, pCBWN, codes for the prM and E glycoproteins of WNV. The plasmid was purified from Escherichia coli XL-1 blue cells with EndoFree Plasmid Giga Kits (QIAGEN, Inc., Santa Clarita, CA) and suspended in 10 mM Tris buffer, pH 8.5, at a concentration of 10.0 mg/mL. For IM vaccination, the DNA vaccine was formulated in phosphate-buffered saline (PBS), pH 7.5, at a concentration of 1.0 mg/mL. For oral exposure, the dry-microencapsulated DNA was suspended in PBS, pH 7.5, at a concentration of 2.0 mg/mL.

Microencapsulation

The method for microencapsulating DNA was adapted from procedures previously described for virus and subunit vaccines and isolated proteins (14–16). We performed all steps with sterile reagents and aseptic technique. Two 10-mg aliquots of WNV cDNA were transferred to sepa-
rate test tubes with enough water to make 9-mL volumes. Resulting suspensions were mixed on a clinical rotator until solution was complete; 1 mL of 0.6% w/v aqueous sodium alginate (Fluka Chemical Co., Ronkonkoma, NY) solution was added to each tube, and the contents of each were gently inverted 20 times. Each DNA/alginate solution was pumped at 1.2 mL/min through a 76-μm orifice in a 1-mm internal diameter glass tube against the side of which a 20-KHz laboratory sonicator probe was firmly pressed. The emerging train of droplets was directed into a modified T-tube, through which a recirculated 40 mL of 0.25% w/v neutral aqueous spermine hydrochloride (Sigma-Aldrich Corp., St. Louis, MO) solution was pumped at 10 mL/min. A placebo microcapsule formulation was prepared by using alginate reagent without DNA. Resulting microcapsule suspensions were allowed to equilibrate for 30 min, pelleted at 500 × g for 20 min, and washed three times by decanting, suspending, and repelleting. Wash liquids were reserved for measuring the DNA that escaped encapsulation. Placebo and vaccine formulations and washes were frozen at −20°C and lyophilized overnight, then suspended in 5 mL of PBS to produce a final concentration of 2 mg/mL of the encapsulated DNA.

Crows

Fish crows (C. ossifragus) were captured with a rocket-propelled net at various locations in Maryland. Birds were transported to a biosafety level 3 laboratory at the U.S. Army Medical Research Institute of Infectious Diseases, allocated into four groups, and placed in stainless steel cages (3–4 birds/cage); blood was collected for evidence of antibodies against flaviviruses. Birds were provided a mixture of cat and dog food ad libitum and water. This diet was supplemented with hardboiled eggs as well as vitamin supplements.

Plaque Assay

Serial 10-fold dilutions of the blood samples from each crow were made in standard diluent (10% heat-inactivated fetal bovine serum in medium 199 with Earle’s salts, NaHCO₃, and antibiotics). These samples were tested for infectious virus by plaque assay on Vero cells in 6-well plates (Costar, Inc., Cambridge, MA) as previously described (17), except that the second overlay, containing neutral red stain, was added 2 or 3 days after the first overlay.

Plaque-Reduction Neutralization Assay

Serum samples were assayed for WNV-specific antibodies by using the plaque-reduction neutralization test (PRNT), as previously described (18). Briefly, each serum sample was diluted 1:10 in standard diluent (as above) and mixed with an equal volume of BA1 (composed of Hanks’ M-199 salts, 1% bovine serum albumin, 350 mg/L of sodium bicarbonate, 100 U/mL of penicillin, 100 mg/L of streptomycin, and 1 mg/L of fungizone in 0.05 M Tris, pH 7.6) containing a suspension of WNV (NY99-4132 strain) at a concentration of approximately 200 plaque-forming units (PFU)/0.1 mL, such that the final serum dilution was 1:20 and the final concentration of WNV (the challenge dose) was approximately 100 PFU/0.1 mL. After 1-h incubation at 37°C, we added the serum/virus mixtures onto Vero monolayers in 6-well plates, 0.1 mL per well in duplicate. We determined the mean percentage of neutralization for each specimen by comparing the number of plaques that developed (see Plaque Assay section) relative to the number of plaques in the challenge dose, as determined by back titration. Preliminary samples were screened for antibodies to WNV in the same manner, as well as for neutralizing antibodies to St. Louis encephalitis virus, a closely related flavivirus that may cross-react serologically with WNV (19) and may partially protect against WNV infection (20).

Experimental Design

The crows were placed in four groups: 1) those inoculated IM with vaccine, 2) those that had oral vaccine, 3) positive controls (i.e., those that received placebo inoculation and viral challenge), and 4) room controls (i.e., those that received placebo inoculation and placebo challenge). After an acclimatization period of approximately 1 month, the 10 crows in group 1 (9 fish crows and 1 American crow [C. brachyrhynchos]) were inoculated IM with 0.5 mg of the DNA vaccine in a total volume of 0.5 mL (0.25 mL in each breast). The 9 crows in group 2 (8 fish crows and 1 American crow) were given 0.5 mg of the encapsulated DNA vaccine orally in 0.25 mL of PBS, and 20 fish crows (groups 3 and 4) were each inoculated and orally exposed as above except that a placebo was used in place of the vaccine. Blood was collected weekly from the jugular vein and the serum tested for neutralizing antibodies to WNV. Six weeks after vaccination, all birds in groups 1, 2, and 3 were inoculated subcutaneously with 0.1 mL of a suspension containing 10⁵ PFU (10⁶ PFU/mL) of the 397-99 strain of WNV, which had been isolated from the brain of an American crow that died in New York City during the fall of 1999 and passaged once in Vero cells before use in this study. The crows in group 4 were inoculated with 0.1 mL of diluent. Three or four crows in each group were bled (0.1 mL) from the jugular vein each day; each bird was bled every third day. Blood samples were added to 0.9 mL of diluent + 10 U of heparin/mL. Blood samples were frozen at −70°C until tested for infectious virus by plaque assay.
Results

Serologic Response

While neutralizing antibodies developed in 5 of the 9 fish crows that received the vaccine by the IM route at the 80% neutralization level for WNV by 14 days after vaccination, neutralizing antibodies to WNV did not develop in any of the remaining fish crows (8 orally exposed to vaccine and 20 placebo-exposed) in the same time period (Table 1). An antibody response at the 78% level developed in one of the remaining IM-vaccinated fish crows. Thus, a serologic response developed in six (67%) of the nine fish crows that received the vaccine by the IM route. However, by day 42 after vaccination, none of these crows retained a response at the 80% neutralization level.

Table 1. Effect of route of administration of a DNA West Nile virus vaccine on the protection of fish crows from challenge with virulent West Nile virus

| Treatment | No. tested | % seropositive | % viremic | Peak viremia | % survival |
|-----------|------------|----------------|-----------|--------------|------------|
| Room control | 10 | 0 | 0 | <1.7 (0.0) | 100 |
| IM | 9 | 56 | 67 | 2.9a (0.4) | 100 |
| Oral | 8 | 0 | 88 | 5.2b (0.8) | 50 |
| Placebo | 10 | 0 | 100 | 4.3b (0.3) | 50 |

Placebo-exposed crows were inoculated IM with 0.5 mg of nonspecific DNA and given 0.5 mg of nonspecific DNA orally. vampire bats inoculated IM with 0.5 mg of nonspecific DNA and given 0.5 mg of nonspecific DNA orally. Placebo-vaccinated group (5 [50%] of 10) and in a second group of unvaccinated fish crows (4 [50%] of 8) tested later (M.J. Turell and M. Bunning, unpub. data). Although no deaths occurred in the IM-vaccinated fish crows, low-level viremia, consistent with that observed in the birds that survived their WNV infection in the other groups, did develop in six of the nine crows. Therefore, a single dose of the DNA vaccine did not elicit complete protection and sterile immunity to WNV infection. Additional studies need to be conducted with multiple doses of vaccination both by the IM as well as by the oral route to determine whether multiple doses might provide greater protection against WNV infection.

Discussion

Although the DNA vaccine failed to induce a long-lasting immune response, fish crows vaccinated with this vaccine by the IM route all survived challenge with virulent WNV. In contrast, oral administration of this vaccine failed to elicit an immune response, nor did it protect fish crows from a lethal challenge with WNV. The death rate in these crows (4 [50%] of 8), was identical to that observed in the placebo-vaccinated group (5 [50%] of 10) and in a second group of unvaccinated fish crows (4 [50%] of 8) tested later (M.J. Turell and M. Bunning, unpub. data). Although no deaths occurred in the IM-vaccinated fish crows, low-level viremia, consistent with that observed in the birds that survived their WNV infection in the other groups, did develop in six of the nine crows. Therefore, a single dose of the DNA vaccine did not elicit complete protection and sterile immunity to WNV infection. Additional studies need to be conducted with multiple doses of vaccination both by the IM as well as by the oral route to determine whether multiple doses might provide greater protection against WNV infection.

During the course of these studies, we determined that we had two American crows mixed in with the fish crows,
one in the oral and one in the IM-vaccinated groups. High viremias (>10^8 PFU/mL of blood) developed in both of these crows, and they died after challenge with virulent WNV. These data, based on a single bird in each group, were not included in the data presented in this report. Both hooded crows (8) and American crows (10) are highly susceptible to infection with WNV with nearly 100% case-fatality rates. In contrast, fish crows appear to be less likely to succumb to the infection.

The continued spread of WNV infection across the United States and reported deaths in raptors and rare captive birds in zoologic parks indicate the need to develop an effective avian vaccine for WNV. To break the transmission cycle, the vaccine must be able to substantially reduce the level of viremia below the level needed to infect a feeding mosquito, which is about 10^5 PFU/mL of blood (21). By this standard, the vaccine performed reasonably well, with no vaccinated fish crow having a recorded viremia >10^6. In contrast, 3 of 10 placebo-vaccinated fish crows had viremias >10^5 PFU/mL of blood, and 5 of 10 had a peak viremia >10^4.8 PFU/mL of blood. However, because the crows were bled only every third day, determining the actual peak viremias in these birds was not possible. If the goal of the vaccine is to protect rare and endangered avian species from death, rather than to prevent transmission, then the occurrence of a low-level viremia is not critical.

Acknowledgments

We thank R. Lind, P. Rico, and S. Duniho for their excellent assistance in caring for the crows; R. Schoepp for his assistance in bleeding the crows; D. Dolhm and J. Velez for technical assistance; J. Blow, R. Schoepp, C. Mores, P. Schneider, and K. Kenyon for editorial assistance; E. Peterson for administrative support; D. Rohrback, S. Bittner, K. Musser, B. Riechard, M. Castle, C. Dade, G. Timko, and B. Davenport for their work in caring for the crows; and the staff at Umberger Farm for allowing us to use their property for the fieldwork.

This work was supported by a grant from The American Bird Conservancy, Pesticides and Birds Campaign, Washington, D.C.

Research was conducted in compliance with the Animal Welfare Act and other Federal statutes and regulations relating to animals and experiments involving animals and adheres to principles stated in the Guide for the Care and Use of Laboratory Animals, National Research Council, 1996. The facility where this research was conducted is fully accredited by the Association for Assessment and Accreditation of Laboratory Animal Care, International.

Dr. Turell is a research entomologist at the United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Maryland. His research interests focus on factors affecting the ability of mosquitoes and other arthropods to transmit viruses.

References

1. Lanciotti RS, Roehrig JT, Deubel V, Smith J, Parker M, Steele K, et al. Origin of the West Nile virus responsible for an outbreak of encephalitis in the Northeastern United States. Science 2000;286:2333–7.
2. Centers for Disease Control and Prevention. Outbreak of West Nile-like viral encephalitis—New York, 1999. MMWR Morb Mortal Wkly Rep 1999;48:845–9.
3. Trock SC, Meade BJ, Glaser AL, O’Guinn ML, Dohm DJ. Potential vectors of West Nile virus. Vet Pathol 2000;37:208–24.
4. Eidson M, Komar N, Sorhage F, Nelson R, Talbot T, Mostashari F, et al. Crow deaths as a sentinel surveillance system for West Nile virus in the northeastern United States, 1999. Emerg Infect Dis 2001;7:615–20.
5. Hayes C. West Nile fever. In: Monath TP, editor. The arboviruses: epidemiology and ecology. Volume V. Boca Raton (FL): CRC Press; 1989. p. 59–88.
6. Turell MJ, Sardelis MR, O’Guinn ML, Dohm DJ. Potential vectors of West Nile virus in North America. In: Mackenzie JS, Barrett ADT, Deubel V, editors. Japanese encephalitis and West Nile viruses, volume 267. Current topics in microbiology and immunology. Berlin: Springer-Verlag; 2002. p. 241–52.
7. Hubalek Z, Halouzka J. West Nile virus—a reemerging mosquito-borne viral disease in Europe. Emerg Infect Dis 1999;5:643–50.
8. Work TH, Hurlbut HS, Taylor RM. Indigenous wild birds of the Nile delta as potential West Nile virus circulating reservoirs. Am J Trop Med HYG 1955;4:872–88.
9. Komar N. West Nile viral encephalitis. Rev Sci Tech Off Int Epiz 2000;19:166–76.
10. McLean RG, Ubico SR, Docherty DE, Hansen WR, Sileo L, McNamara T. West Nile virus transmission and ecology in birds. Ann N Y Acad Sci 2001;951:54–7.
11. Marfin AA, Petersen LR, Eidson M, Miller J, Hadley J, Farello C, et al. Widespread West Nile virus activity, eastern United States, 2000. Emerg Infect Dis 2001;7:730–5.
12. Steele KE, Linn MJ, Schoepp RJ, Komar N, Geisbert TW, Manduca RM, et al. Pathology of fatal West Nile virus infections in native and exotic birds during the 1999 outbreak in New York City, New York. Vet Pathol 2000;37:208–24.
13. Chang GJ, Davis BS, Hunt AR, Holmes DA, Kuno G. Flavivirus DNA vaccines: current status and potential. Ann N Y Acad Sci 2001;951:272–85.
14. Moser CA, Speaker TJ, Offit PA. Effect of aqueous based microencapsulation on protection against EDIM rotavirus challenge in mice. J Virol 1998;72:3859–62.
15. Patil RT, Speaker TJ. Water based microsphere delivery system for proteins. J Pharm Sci 2000;89:9–15.
16. Speaker TJ, Clark HF, Moser CA, Offit PA, Campos M, Frenchik PJ. U.S. Patent 6,270,800 aqueous solvent based encapsulation of a bovine herpes virus type-1 subunit vaccine. Aug 7, 2001.
17. Gargan TP II, Bailey CL, Higbee GA, Gad A, El Said S. The effect of laboratory colonization on the vector pathogen interaction of Egyptian Culex pipiens and Rift Valley fever virus. Am J Trop Med Hyg 1983;32:1154–63.
18. Beaty BJ, Calisher CH, Shope RE. Arboviruses. In: Schmidt NJ, Emmons RW, editors. Diagnostic procedures for viral, rickettsial and chlamydial infections. 6th ed. Washington: American Public Health Association; 1989. p. 797–855.
19. Calisher CH. Antigenic classification and taxonomy of flaviviruses (family Flaviviridae) emphasizing a universal system for the taxonomy of viruses causing tick-borne encephalitis. Acta Virol 1988;32:469–78.
20. Tesh RB, Travassos da Rosa AP, Guzman H, Araujo TP, Xiao SY. Immunization with heterologous flaviviruses protective against fatal West Nile encephalitis. Emerg Infect Dis 2002;8:245–51.
21. Turell MJ, O’Guinn ML, Dohm DJ, Jones JW. Vector competence of North American mosquitoes (Diptera: Culicidae) for West Nile virus. J Med Entomol 2001;38:130–4.

Address for correspondence: Michael J. Turell, Department of Vector Assessment, Virology Division, USAMRIID, 1425 Porter Street, Fort Detrick, MD 21702-5011, USA; fax: (301) 619-2290; email: michael.turell@det.amedd.army.mil

Emerging Infectious Diseases • Vol. 9, No. 9, September 2003 1081